Cagrilintide 5mg
$54.99$50.99
Cagrilintide is a long-lasting amylin and calcitonin receptor agonist (DACRA) designed to address obesity and type 2 diabetes. It mimics the natural hormone amylin, which helps control appetite and slows down gastric emptying, thereby promoting feelings of fullness and decreasing food intake. Administered via a weekly injection, cagrilintide has demonstrated significant weight loss results, particularly when used in combination with the GLP-1 receptor agonist semaglutide in the investigational treatment CagriSema. Clinical trials have shown greater weight loss and better blood sugar management compared to using each drug separately. The most frequent side effects include mild gastrointestinal issues, and currently, the drug is in late-stage clinical development.